{{Rsnum
|rsid=7579899
|Gene=EPAS1
|Chromosome=2
|position=46310465
|Orientation=plus
|GMAF=0.4389
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=EPAS1
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 10.6 | 49.6 | 39.8
| HCB | 76.6 | 22.6 | 0.7
| JPT | 73.5 | 25.7 | 0.9
| YRI | 49.0 | 41.5 | 9.5
| ASW | 29.8 | 59.6 | 10.5
| CHB | 76.6 | 22.6 | 0.7
| CHD | 70.6 | 26.6 | 2.8
| GIH | 34.7 | 42.6 | 22.8
| LWK | 30.9 | 51.8 | 17.3
| MEX | 19.0 | 51.7 | 29.3
| MKK | 29.5 | 55.1 | 15.4
| TSI | 8.8 | 51.0 | 40.2
| HapMapRevision=28
}}{{PMID Auto GWAS
|PMID=21131975
|Trait=None
|Title=Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3
|RiskAllele=
|Pval=2E-9
|OR=1.1500
|ORtxt=[1.10-1.21]
|OA=1
}}

23andMe reports that [[rs7579899]](A,A) homozygotes are 1.15 times more likely, and (G,G) homozygotes 1.15 times less likely, than (A,G) heterozygotes to develop [[renal cell carcinoma]] (a form of [[kidney cancer]]). {{PMID|21131975|OA=1
}}

{{PMID Auto
|PMID=22131124
|Title=Chromosome 11q13.3 variant modifies renal cell cancer risk in a Chinese population
}}

{{PMID Auto
|PMID=22113997
|Title=The chromosome 2p21 region harbors a complex genetic architecture for association with risk for renal cell carcinoma
|OA=1
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Illumina Human 1M}}